Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;32(5):e13041.
doi: 10.1111/dth.13041. Epub 2019 Aug 12.

Urticarial rash, fever, and arthritis: A case of refractory Adult-onset Still's disease with good response to tocilizumab

Affiliations
Review

Urticarial rash, fever, and arthritis: A case of refractory Adult-onset Still's disease with good response to tocilizumab

Bartlomiej Wawrzycki et al. Dermatol Ther. 2019 Sep.

Abstract

Adult-onset Still's disease (AOSD) is a rare, systemic inflammatory disorder of not completely understood etiology. Aberrant activation of the innate immune system and overproduction of several pro-inflammatory mediators are considered a critical component in disease pathogenesis. AOSD still poses a challenge due to the broad range of differential diagnoses and no specific biomarkers. Four cardinal symptoms are quotidian spiking fever, joint involvement, evanescent salmon pink-rash rash, and leukocytosis with neutrophilia. We present a case of a 61-year-old female with a recurrent urticarial rash accompanied by attacks of high fever, tender joints, sore throat, enlarged liver, elevated inflammatory reactants, and hyperferritinemia. After an extensive workup, the patient fulfilled the criteria of AOSD. She was refractory to the glucocorticosteroids and disease-modifying anti-rheumatic drugs (DMARDs). Finally, after several unsuccessful attempts to achieve disease control with traditional DMAR's administration of Tocilizumab (TCZ), a humanized anti-IL-6 receptor antagonist resulted in substantial disease improvement. Since skin manifestations are a common feature of AOSD, it should be among differential diagnoses in patients with skin lesions and constitutional symptoms. Biologic agents represent a significant therapeutic advance in patients with AOSD refractory to conventional therapy.

Keywords: Adult-onset Still's disease (AOSD); anti-IL-6; atypical persistent skin eruptions (APSEs); evanescent skin eruption (ESE); multigenic autoinflammatory disease; tocilizumab (TCZ).

PubMed Disclaimer

Similar articles

Cited by

References

REFERENCES

    1. Bywaters, E. G. (1971). Still's disease in the adult. Annals of the Rheumatic Diseases, 30, 121-133.
    1. Castañeda, S., Martínez-Quintanilla, D., Martín-Varillas, J. L., García-Castañeda, N., Atienza-Mateo, B., & González-Gay, M. A. (2019). Tocilizumab for the treatment of adult-onset Still's disease. Expert Opinion on Biological Therapy, 19, 273-286.
    1. Chen, D.-Y., Lan, J.-L., Lin, F.-J., & Hsieh, T.-Y. (2004). Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. The Journal of Rheumatology, 31, 2189-2198.
    1. Fautrel, B., Zing, E., Golmard, J.-L., Moel, G. L., Bissery, A., Rioux, C., … Bourgeois, P. (2002). Proposal for a new set of classification criteria for adult-onset still disease. Medicine, 81, 194-200.
    1. Feist, E., Mitrovic, S., & Fautrel, B. (2018). Mechanisms, biomarkers and targets for adult-onset Still's disease. Nature Reviews Rheumatology, 14, 603-618.

MeSH terms

LinkOut - more resources